| Description | Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab selectively depletes effector memory T cells and promotes relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis. |
| In vitro | Siplizumab（MEDI-507；0.00001-10 nM）能够结合至FcγR并诱导信号传导[1]。此外，Siplizumab（0.0001-10 μg/mL）介导细胞耗竭，并降低T细胞增殖[1]。 |
| Synonyms | MEDI-507 |
| molecular weight | N/A |
| CAS | 288392-69-8 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Binder C, et, al. Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro. Front Immunol. 2020 Nov 11;11:592553. |